Evidence map›Paper›PMID 42193316›Full record

ArticleBiomedicines2026

Osteopontin-4 (OPN-4) Suppresses Tumor Progression Features Whilst Sensitizing c643 Anaplastic Thyroid Cells to Sorafenib.

Gabriela Ribeiro Silva, Amanda Lewis Rubim, Flavia da Cunha Vasconcelos, Luciana Bueno Ferreira, John Greenman, Etel Rodrigues Pereira Gimba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabriela Ribeiro SilvaPrograma de Pós-Graduação em Ciências Biomédicas, Fisiologia e Farmacologia, Instituto Biomédico, Niterói CEP 24210-130, Brazil.ORCID 0000-0003-3047-1092
Amanda Lewis RubimGrupo de Hemato-Oncologia Molecular, Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro CEP 20230-130, Brazil.
Flavia da Cunha VasconcelosGrupo de Hemato-Oncologia Molecular, Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro CEP 20230-130, Brazil.
Luciana Bueno FerreiraGrupo de Hemato-Oncologia Molecular, Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro CEP 20230-130, Brazil.ORCID 0000-0001-9120-7004
John GreenmanCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.ORCID 0000-0002-6003-6051
Etel Rodrigues Pereira GimbaPrograma de Pós-Graduação em Ciências Biomédicas, Fisiologia e Farmacologia, Instituto Biomédico, Niterói CEP 24210-130, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul E-26/210.394/2014, E-26/010.002007/2014, E-26/203.204/2015, E-26/202.798/2017, SEI-26003/004812/2021 and Nº: SEI-260003/001554/2022Ministério da Saúde not applicableNational Council for Scientific and Technological Development 310591/2014-7,435783/2018-1, 307427/2022-6 and 408314/2021-4PROPPI/UFF Not applicable
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anaplastic thyroid carcinomamicrofluidic deviceOPN-4osteopontinspheroidssplicingsplicing isoforms

Identifiers

PMID42193316
PMCPMC13203564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.